What is the correct way to manage oral immunotherapy for
food allergy during the COVID-19 pandemic?
In patients diagnosed with COVID-19 or cases with suspected SARS-CoV-2
infection, oral immunotherapy dosing should continue as indicated in the
dosing plan and in coordination with the treating physician. Oral
immunotherapy can be continued in non-infected patients and those who
have recovered from COVID-19. In areas with high level of SARS-CoV-2
community transmission, visits to the allergy clinic for oral
immunotherapy up-dosing should be postponed. 108,118